Efficacy of MT204 in a humanized mouse model of psoriasis - Module 2

Completed

• Conditions: flaking disease; psoriasis; 10003816; 10014982

• Registration Number: NL-OMON34174
• Lead Sponsor: Micromet AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Psoriasis patients: Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 6). Patients are allowed to use local corticosteroids or ointments to prevent dry skin (see Appendix 2).

Exclusion Criteria

Psoriasis patients: These patients have not received light therapy or another form of systemic treatment (methotrexate, cyclosporin A, anti-TNF treatments). Gender or age of the adults are not exclusion criteria (see Appendix 2).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Effect on the psoriatic process is tested by histology and immuno-histochemical<br /><br>techniques in the transplanted biopsies. Main read-out is epidermal thickness.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Serum markers in blood of transplanted mice will be studied together with<br /><br>markers on cultured cells from psoriasis patients. Possibly also inflammatory<br /><br>markers in the skin tissue will be evaluated.</p><br>